Question 1

Does insurance cover Wegovy for weight loss in 2026?

Accepted Answer

Approximately 25 to 30% of commercially insured Americans have insurance coverage for Wegovy in 2026. Coverage has improved significantly from 15% in 2023, driven by employer plan expansions and growing recognition of obesity as a chronic disease. The most common coverage scenario requires prior authorisation: your physician submits documentation of your BMI, qualifying health conditions, and evidence of previous weight loss attempts. The fastest way to check your specific coverage is calling the member services number on your insurance card and asking about your plan formulary for Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide).

Question 2

Does Medicare cover GLP-1 weight loss medication?

Accepted Answer

Medicare coverage for GLP-1 medications is limited but expanding in 2026. Medicare Part D covers Zepbound for patients with established cardiovascular disease and a BMI of 27 or higher, added in 2024 following the SELECT trial. Wegovy is not yet covered by Medicare for weight loss alone. Ozempic and Mounjaro are covered for type 2 diabetes management. Some Medicare Advantage plans cover GLP-1 medications for weight management — check your specific plan formulary. The most affordable Medicare-eligible path to semaglutide for weight loss is often the NovoCare patient assistance program or compounded semaglutide through telehealth.

Question 3

How do I appeal an insurance denial for GLP-1 medication?

Accepted Answer

Appealing an insurance denial for GLP-1 medication has a 40 to 60% success rate when properly documented. The key steps: first, get the denial reason in writing with the specific clinical criteria not met. Second, have your physician write a letter of medical necessity citing your BMI, qualifying comorbidities, and previous weight loss interventions attempted. Third, include objective supporting documentation such as blood pressure readings, HbA1c results, or sleep study data. Submit the appeal within the deadline, typically 30 to 180 days. If the first-level appeal fails, request an external independent review. The Obesity Action Coalition provides free template letters and guidance for appeals.

Question 4

What GLP-1 medications does insurance typically cover?

Accepted Answer

Insurance formulary coverage for GLP-1 medications in 2026 varies by drug and indication. Ozempic (semaglutide for diabetes) is covered on most commercial and Medicare Part D formularies. Mounjaro (tirzepatide for diabetes) is covered on approximately 70% of commercial formularies. Wegovy (semaglutide for weight loss) is covered on 25 to 30% of commercial plans. Zepbound (tirzepatide for weight loss) is covered on approximately 20 to 25% of commercial plans and Medicare for cardiovascular risk patients. Some patients with type 2 diabetes have better insurance coverage outcomes with diabetes-indicated prescriptions than the weight-loss-specific versions.

Question 5

What is the out-of-pocket cost for Wegovy with insurance?

Accepted Answer

With insurance coverage, the average out-of-pocket cost for Wegovy in 2026 depends on your plan tier and cost-sharing structure. On plans with preferred formulary status, copays typically range from $25 to $100 per month after meeting your deductible. Plans with Wegovy on a non-preferred tier often charge 20 to 40% coinsurance. The Novo Nordisk savings card reduces commercial copays to a maximum of $99 per month for eligible patients. Medicare patients cannot use manufacturer savings cards. If your annual deductible has not been met, you may pay close to list price until it is reached, after which insurance kicks in.

GLP-1 Insurance
Coverage Estimator

Does insurance cover GLP-1 for weight loss in 2026?

Medicare and Medicaid coverage

GLP-1 InsuranceCoverage Estimator

Does insurance cover GLP-1 for weight loss in 2026?

Medicare and Medicaid coverage

GLP-1 Insurance
Coverage Estimator